Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Lenvatinib in Advanced Endometrial Cancer
NCT05824481Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in endometrial cancer (EC), sponsored by Sun Yat-sen University. Started May 2023; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05824481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824481.